1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors.
Saved in:
| Title: | 1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors. |
|---|---|
| Authors: | Marron, T.U.1 (AUTHOR), Misleh, J.G.2 (AUTHOR), C. chen3 (AUTHOR), Wainberg, Z.A.4 (AUTHOR), Powderly, J.5 (AUTHOR), Boccia, R.6 (AUTHOR), Gordon, M.7 (AUTHOR), Segar, J.8 (AUTHOR), Csiki, I.9 (AUTHOR), Schanzer, J.M.10 (AUTHOR), O'Toole, L.11 (AUTHOR), Huang, N.9 (AUTHOR), Seppa, J.9 (AUTHOR), Glenn, J.12 (AUTHOR), Klumpp, K.13 (AUTHOR), Spira, A.I.14 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS623-S624. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
